190 related articles for article (PubMed ID: 35716369)
21. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
22. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
23. Identification of tumor microenvironment-related genes in lower-grade gliomas by mining TCGA database.
Liang H; Huang C
Transl Cancer Res; 2020 Aug; 9(8):4583-4595. PubMed ID: 35117823
[TBL] [Abstract][Full Text] [Related]
24. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
[TBL] [Abstract][Full Text] [Related]
25. Classification of diffuse lower-grade glioma based on immunological profiling.
Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W
Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361
[TBL] [Abstract][Full Text] [Related]
26. Automated Grading of Gliomas using Deep Learning in Digital Pathology Images: A modular approach with ensemble of convolutional neural networks.
Ertosun MG; Rubin DL
AMIA Annu Symp Proc; 2015; 2015():1899-908. PubMed ID: 26958289
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance and immune correlation of SLC10A3 in low-grade gliomas revealed by bioinformatic analysis and multiple immunohistochemistry.
He Y; Song J; Qin Y; Mao D; Ding D; Wu S; Wu H
Aging (Albany NY); 2023 May; 15(9):3771-3790. PubMed ID: 37166424
[TBL] [Abstract][Full Text] [Related]
28. Radiomics MRI Phenotyping with Machine Learning to Predict the Grade of Lower-Grade Gliomas: A Study Focused on Nonenhancing Tumors.
Park YW; Choi YS; Ahn SS; Chang JH; Kim SH; Lee SK
Korean J Radiol; 2019 Sep; 20(9):1381-1389. PubMed ID: 31464116
[TBL] [Abstract][Full Text] [Related]
29. Structuring and validating a prognostic model for low-grade gliomas based on the genes for plasma membrane tension.
Li J; Lv F; Jin T
Front Neurol; 2022; 13():1024869. PubMed ID: 36408514
[TBL] [Abstract][Full Text] [Related]
30. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
31. Immune cell infiltration and inflammatory landscape in primary brain tumours.
Luce A; Abate M; Scognamiglio G; Montella M; Iervolino D; Campione S; Di Mauro A; Sepe O; Gigantino V; Tathode MS; Ferrara G; Monaco R; De Dominicis G; Misso G; Gentile V; Franco R; Zappavigna S; Caraglia M
J Transl Med; 2024 May; 22(1):521. PubMed ID: 38816839
[TBL] [Abstract][Full Text] [Related]
32. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
33. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
34. Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma.
Wang X; Huang Y; Li S; Zhang H
Front Immunol; 2022; 13():1027154. PubMed ID: 36275754
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
36. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Tu Z; Ji Q; Han Q; Long X; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2022 Sep; 22(1):973. PubMed ID: 36096781
[TBL] [Abstract][Full Text] [Related]
38. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.
Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B
Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059
[TBL] [Abstract][Full Text] [Related]
39. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
40. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
